PPARγ agonists: Potential as therapeutics for neovascular retinopathies

PPAR Research

Volumn , Issue , 2008, Pages

  Pershadsingh, Harrihar A ^a,b   Moore, David M ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c KERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; CANDESARTAN; EPROSARTAN; GLITAZONE DERIVATIVE; IRBESARTAN; LOSARTAN; OLMESARTAN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; ROSIGLITAZONE; TELMISARTAN; TROGLITAZONE; VALSARTAN;

ANTIINFLAMMATORY ACTIVITY; AUTOREGULATION; BLINDNESS; DIABETIC RETINOPATHY; DRUG EFFICACY; DRUG SAFETY; EDEMA; FLUID RETENTION; GENE EXPRESSION; GLUCOSE METABOLISM; GLYCATION; HORMONE ACTION; HUMAN; HYPERTENSION; LASER COAGULATION; LIPID METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PLASMA VOLUME; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RETINA MACULA DEGENERATION; RETINA MACULA EDEMA; RETINA NEOVASCULARIZATION; REVIEW; SIDE EFFECT; SUBRETINAL NEOVASCULARIZATION; VASODILATATION; VISUAL IMPAIRMENT; WEIGHT GAIN;

EID: 45349084588     PISSN: 16874757     EISSN: 16874765     Source Type: Journal    
DOI: 10.1155/2008/164273     Document Type: Review

References (125)

1. Eming S. A.
2. Gupta K.
3. Dorrell M., Uusitalo-Jarvinen H., Aguilar E., Friedlander M., Ocular Neovascularization: basic mechanisms and therapeutic advances Survey of Ophthalmology 2007 52 1 supplement 1 S3 S19
4. Kempen J. H.
5. Friedman D. S.
6. Mohamed Q., Gillies M. C., Wong T. Y.
7. US Centers for Disease Control and Prevention, National diabetes fact sheet: general information and national estimates on diabetes in the United States. Department of Health and Human Services, Centers for Disease Control and Prevention; Atlanta, Ga, USA 2005
8. International Diabetes Federation, Diabetes Atlas. 2003, http://www.eatlas.idf.org/webdata/docs/atlas%202003-summary.pdf
9. Klein B. E. K.
10. Matthews D. R.
11. Sjølie A. K., Stephenson J., Aldington S., Retinopathy and vision loss in insulin-dependent diabetes in Europe: the EURODIAB IDDM Complications Study Ophthalmology 1997 104 2 252 260
12. Ciulla T. A., Amador A. G., Zinman B.
13. Zarbin M. A.
14. Donati G.
15. Nowak J. Z.
16. Emerson M. V., Lauer A. K., Emerging therapies for the treatment of neovascular age-related macular degeneration and diabetic macular edema BioDrugs 2007 21 4 245 257
17. Mangelsdorf D. J., Thummel C., Beato M., The nuclear receptor superfamily: the second decade Cell 1995 83 6 835 839
18. Kliewer S. A., Forman B. M., Blumberg B., Differential expression and activation of a family of murine peroxisome proliferator-activated receptors Proceedings of the National Academy of Sciences of the United States of America 1994 91 15 7355 7359
19. Lehmann J. M., Moore L. B., Smith-Oliver T. A., Wilkison W. O., Willson T. M., Kliewer S. A., An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor- γ (PPAR- γ) Journal of Biological Chemistry 1995 270 22 12953 12956
20. Altiok S., Xu M., Spiegelman B. M., PPAR γ induces cell cycle withdrawal: inhibition of E2F/DP DNA-binding activity via down-regulation of PP2A Genes & Development 1997 11 15 1987 1998
21. Pershadsingh H. A., Pharmacological peroxisome proliferator-activated receptor γ ligands: emerging clinical indications beyond diabetes Expert Opinion in Investigational Drugs 1999 8 11 1859 1872
22. Gelman L., Fruchart J.-C., Auwerx J.
23. Chinetti G., Fruchart J.-C., Staels B.
24. Michalik L.
25. Kostadinova R., Wahli W., Michalik L.
26. Sarlos S., Wilkinson-Berka J. L.
27. Senanayake P.
28. Nagai N., Noda K., Urano T., Selective suppression of pathologic, but not physiologic, retinal neovascularization by blocking the angiotensin II type 1 receptor Investigative Ophthalmology & Visual Science 2005 46 3 1078 1084
29. Chen P., Scicli G. M., Guo M., Role of angiotensin II in retinal leukostasis in the diabetic rat Experimental Eye Research 2006 83 5 1041 1051
30. Clermont A., Bursell S.-E., Feener E. P.
31. Nagai N., Oike Y., Izumi-Nagai K., Suppression of choroidal neovascularization hy inhibiting angiotensin-converting enzyme: minimal role of bradykinin Investigative Ophthalmology & Visual Science 2007 48 5 2321 2326
32. Kurihara T., Ozawa Y., Shinoda K., Neuroprotective effects of angiotensin II type 1 receptor (AT1R) blocker, telmisartan, via modulating AT1R and AT2R signaling in retinal inflammation Investigative Ophthalmology & Visual Science 2006 47 12 5545 5552
33. Nagai N., Izumi-Nagai K., Oike Y., Suppression of diabetes-induced retinal inflammation by blocking the angiotensin II type 1 receptor or its downstream nuclear factor- κ B pathway Investigative Ophthalmology & Visual Science 2007 48 9 4342 4350
34. Sugiyama T.
35. Wilkinson-Berka J. L.
36. Phipps J. A., Wilkinson-Berka J. L., Fletcher E. L.
37. Benson S. C., Pershadsingh H. A., Ho C. I., Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPAR γ -modulating activity Hypertension 2004 43 5 993 1002
38. Schupp M., Janke J., Clasen R., Unger T., Kintscher U.
39. Schupp M., Clemenz M., Gineste R., Molecular characterization of new selective peroxisome proliferator-activated receptor γ modulators with angiotensin receptor blocking activity Diabetes 2005 54 12 3442 3452
40. Imayama I., Ichiki T.
41. Yamagishi S.-I.
42. Amano S., Yamagishi S.-I.
43. Yamagishi S.-I.
44. Yamagishi S.-I.
45. Nagai N., Oike Y., Izumi-Nagai K., Angiotensin II type 1 receptor-mediated inflammation is required for choroidal neovascularization Arteriosclerosis, Thrombosis, and Vascular Biology 2006 26 10 2252 2259
46. Zhou J., Wilson K. M., Medh J. D., Genetic analysis of four novel peroxisome proliferator receptor- γ splice variants in monkey macrophages Biochemical and Biophysical Research Communications 2002 293 1 274 283
47. Elbrecht A.
48. Vidal-Puig A. J.
49. Fajas L., Auboeuf D., Raspé E., The organization, promoter analysis, and expression of the human PPAR γ gene Journal of Biological Chemistry 1997 272 30 18779 18789
50. Braissant O., Foufelle F., Scotto C., Dauca M., Wahli W., Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR- α,-β, and-γ in the adult rat Endocrinology 1996 137 1 354 366
51. Michalik L., Desvergne B., Dreyer C., Gavillet M., Laurini R. N., Wahli W., PPAR expression and function during vertebrate development International Journal of Developmental Biology 2002 46 1 105 114
52. Pershadsingh H. A., Benson S. C., Marshall B., Ocular diseases and peroxisome proliferatoractivated receptor- γ (PPAR- γ) in mammalian eye Society for Neuroscience Abstracts 1999 25, part 2 2193
53. Sarayba M. A., Li L., Tungsiripat T., Inhibition of corneal neovascularization by a peroxisome proliferator-activated receptor- γ ligand Experimental Eye Research 2005 80 3 435 442
54. Muranaka K., Yanagi Y.
55. Xin X., Yang S., Kowalski J., Gerritsen M. E., Peroxisome proliferator-activated receptor γ ligands are potent inhibitors of angiogenesis in vitro and in vivo Journal of Biological Chemistry 1999 274 13 9116 9121
56. Giaginis C., Margeli A., Theocharis S.
57. Fujita T., Sugiyama Y., Taketomi S., Reduction of insulin resistance in obese and/or diabetic animals by 5-[4-(1-methylcyclohexylmethoxy)benzyl]- thiazolidine-2,4-dione (ADD-3878, U-63,287, ciglitazone), a new antidiabetic agent Diabetes 1983 32 9 804 810
58. Nesto R. W., Bell D., Bonow R. O., Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association Circulation 2003 108 23 2941 2948
59. Rocchi S., Auwerx J., Peroxisome proliferator-activated receptor-gamma: a versatile metabolic regulator Annals of Medicine 1999 31 5 342 351
60. Delerive J. C., Fruchart J. C., Staels B., Peroxisome proliferator-activated receptors in inflammation control Journal of Endocrinology 2001 169 3 453 459
61. Gervois P.
62. Touyz R. M.
63. Debril M.-B., Renaud J.-P., Fajas L., Auwerx J., The pleiotropic functions of peroxisome proliferator-activated receptor γ Journal of Molecular Medicine 2001 79 1 30 47
64. Glass C. K., Potential roles of the peroxisome proliferator-activated receptor- γ in macrophage biology and atherosclerosis Journal of Endocrinology 2001 169 3 461 464
65. Pfützner A.
66. Varani J., Bhagavathula N., Ellis C. N., Pershadsingh H. A., Thiazolidinediones: potential as therapeutics for psoriasis and perhaps other hyperproliferative skin disease Expert Opinion on Investigational Drugs 2006 15 11 1453 1468
67. Wada K., Nakajima A., Blumberg R. S.
68. Harrison S. A.
69. Watson G. S., Cholerton B. A., Reger M. A., Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study American Journal of Geriatric Psychiatry 2005 13 11 950 958
70. Giannini S.
71. Aoun P., Simpkins J. W., Agarwal N.
72. Hammes H.-P.
73. Klein R., Klein B. E. K., Moss S. E., Cruickshanks K. J., The Wisconsin epidemiologic study of diabetic retinopathy: XVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes Ophthalmology 1998 105 10 1801 1815
74. Davidson J. A.
75. Aiello L. M.
76. Joussen A. M., Smyth N., Niessen C., Pathophysiology of diabetic macular edema Developments in Ophthalmology 2007 39 1 12
77. Murata T., Hata Y., Ishibashi T., Response of experimental retinal neovascularization to thiazolidinediones Archives of Ophthalmology 2001 119 5 709 717
78. Schlingemann R. O.
79. Bourla D. H., Young T. A.
80. Hogg R. E., Woodside J. V., Gilchrist S. E., Cardiovascular disease and hypertension are strong risk factors for choroidal neovascularization. Ophthalmology. In press
81. Willson T. M.
82. Wexler R. R., Greenlee W. J., Irvin J. D., Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy Journal of Medicinal Chemistry 1996 39 3 625 656
83. Murata T., He S., Hangai M., Peroxisome proliferator-activated receptor- γ ligands inhibit choroidal neovascularization Investigative Ophthalmology & Visual Science 2000 41 8 2309 2317
84. Colucciello M.
85. Ryan E. H. Jr., Han D. P., Ramsay R. C., Diabetic macular edema associated with glitazone use Retina 2006 26 5 562 570
86. Kirch W., Horn B., Schweizer J., Comparison of angiotensin II receptor antagonists European Journal of Clinical Investigation 2001 31 8 698 706
87. Pershadsingh H. A.
88. Kurtz T. W.
89. Cianchetti S., Del Fiorentino A., Colognato R., Di Stefanoa R., Franzonic F., Pedrinellia R., Anti-inflammatory and anti-oxidant properties of telmisartan in cultured human umbilical vein endothelial cells Atherosclerosis 2008 198 1 22 28
90. Shao J., Nangaku M.
91. Gohlke P.
92. Kliewer S. A., Xu H. E., Lambert M. H., Willson T. M., Peroxisome proliferator-activated receptors: from genes to physiology Recent Progress in Hormone Research 2001 56 239 263
93. Berger J., Moller D. E., The mechanisms of action of PPARs Annual Review of Medicine 2002 53 409 435
94. Berger J. P., Petro A. E., Macnaul K. L., Distinct properties and advantages of a novel peroxisome proliferator-activated protein γ selective modulator Molecular Endocrinology 2003 17 4 662 676
95. Oberfield J. L., Collins J. L., Holmes C. P., A peroxisome proliferator-activated receptor γ ligand inhibits adipocyte differentiation Proceedings of the National Academy of Sciences of the United States of America 1999 96 11 6102 6106
96. McKenna N. J., O'Malley B. W.
97. de Gasparo M., Catt K. J., Inagami T., Wright J. W., Unger T., International union of pharmacology. XXIII. The angiotensin II receptors Pharmacological Reviews 2000 52 3 415 472
98. Wagner J., Danser A. H. J., Derkx F. H., Demonstration of renin mRNA, angiotensinogen mRNA, and angiotensin converting enzyme mRNA expression in the human eye: evidence for an intraocular renin-angiotensin system British Journal of Ophthalmology 1996 80 2 159 163
99. Danser A. H. J., van den Dorpel M. A., Deinum J., Renin, prorenin, and immunoreactive renin in vitreous fluid from eyes with and without diabetic retinopathy Journal of Clinical Endocrinology and Metabolism 1989 68 1 160 167
100. Danser A. H., Derkx F. H., Admiraal P. J., Deinum J., de Jong P. T., Schalekamp M. A., Angiotensin levels in the eye Investigative Ophthalmology & Visual Science 1994 35 3 1008 1018
101. Funatsu H., Yamashita H., Nakanishi Y., Hori S., Angiotensin II and vascular endothelial growth factor in the vitreous fluid of patients with proliferative diabetic retinopathy British Journal of Ophthalmology 2002 86 3 311 315
102. Senanayake P.
103. Wilkinson-Berka J. L.
104. Otani A., Takagi H.
105. Castellon R., Hamdi H. K., Sacerio I., Aoki A. M., Kenney M. C., Ljubimov A. V., Effects of angiogenic growth factor combinations on retinal endothelial cells Experimental Eye Research 2002 74 4 523 535
106. Paques M., Massin P., Gaudric A., Growth factors and diabetic retinopathy Diabetes & Metabolism 1997 23 2 125 130
107. Pinto C. C., Silva K. C., Biswas S. K., Martins N., Lopes de Faria J. B., Lopes de Faria J. M., Arterial hypertension exacerbates oxidative stress in early diabetic retinopathy Free Radical Research 2007 41 10 1151 1158
108. Silva K. C., Pinto C. C., Biswas S. K., Souza D. S., Lopes de Faria J. B., Lopes de Faria J. M.
109. Wong T. Y., Mitchell P., The eye in hypertension The Lancet 2007 369 9559 425 435
110. Pershadsingh H. A., Telmisartan, PPAR- γ and retinal neovascularization Investigative Ophthalmology & Visual Science 2006 February. Letter to the Editor, http://www.iovs.org/cgi/eletters/46/3/1078
111. Derosa G.
112. Derosa G.
113. Sugimoto K., Qi N. R., Kazdová L., Pravenec M., Ogihara T., Kurtz T. W.
114. Geroski D. H., Edelhauser H. F.
115. Myles M. E., Neumann D. M., Hill J. M.
116. Hsu J.
117. van Leeuwen R., Ikram M. K., Vingerling J. R., Witteman J. C. M., Hofman A., de Jong P. T.
118. Klein R., Klein B. E., Tomany S. C., Cruickshanks K. J., The association of cardiovascular disease with the long-term incidence of age-related maculopathy: the Beaver Dam Eye Study Ophthalmology 2003 110 6 1273 1280
119. Nissen S. E.
120. Home P. D., Pocock S. J., Beck-Nielsen H., Rosiglitazone evaluated for cardiovascular outcomes-an interim analysis The New England Journal of Medicine 2007 357 1 28 38
121. Lago R. M., Singh P. P., Nesto R. W.
122. Erdmann E.
123. Dormandy J. A., Charbonnel B., Eckland D. J., Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial The Lancet 2005 366 9493 1279 1289
124. Zhang F.
125. Sjølie A. K., Porta M., Parving H. H., The DIabetic REtinopathy Candesartan Trials (DIRECT) Programme: baseline characteristics Journal of the Renin-Angiotensin-Aldosterone System 2005 6 1 25 32